Stem Cells http://www.peprotech.com/
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hirano, T.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hirano, T.

International Journal of Cell Cloning, Vol 9, 166-184, Copyright © 1991 by AlphaMed Press

REVIEWS

Interleukin 6 (IL-6) and its receptor: their role in plasma cell neoplasias

T Hirano
Division of Molecular Oncology, Biomedical Research Center, Osaka University Medical School, Japan.

Interleukin 6 (IL-6) is a multifunctional cytokine regulating immune response acute phase reaction and hematopoiesis. IL-6 plays a critical role in B cell differentiation to plasma cells and is a potent growth factor for plasmacytoma and myeloma. Abnormal production of IL-6 has been suggested to be involved in polyclonal plasma cell abnormalities and plasma cell neoplasias. The deregulated expression of the IL-6 gene in transgenic mice resulted in the generation of malignant plasmacytoma. Based on these findings, it could be considered that continuous IL-6 gene expression plays an essential role in a multistep oncogenesis of plasma cell neoplasias. The role of IL-6 and its receptor in the generation of plasma cell neoplasias and the mechanisms of the IL-6 gene expression and IL-6 receptor-mediated signal transduction are described.


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
B. M. Birmann, R. M. Tamimi, E. Giovannucci, B. Rosner, D. J. Hunter, P. Kraft, C. Mitsiades, K. C. Anderson, and G. A. Colditz
Insulin-like Growth Factor-1- and Interleukin-6-related Gene Variation and Risk of Multiple Myeloma
Cancer Epidemiol. Biomarkers Prev., January 1, 2009; 18(1): 282 - 288.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. David, S.-Y. Sun, E. K. Waller, J. Chen, F. R. Khuri, and S. Lonial
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT
Blood, December 15, 2005; 106(13): 4322 - 4329.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Asosingh, H. De Raeve, I. Van Riet, B. Van Camp, and K. Vanderkerken
Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis
Blood, April 15, 2003; 101(8): 3136 - 3141.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. Metzger, T. Hassin, V. Barash, O. Pappo, and T. Chajek-Shaul
Reduced body fat and increased hepatic lipid synthesis in mice bearing interleukin-6-secreting tumor
Am J Physiol Endocrinol Metab, November 1, 2001; 281(5): E957 - E965.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
M. B. Rettig, H. J. Ma, R. A. Vescio, M. Põld, G. Schiller, D. Belson, A. Savage, C. Nishikubo, C. Wu, J. Fraser, et al.
Kaposi's Sarcoma-Associated Herpesvirus Infection of Bone Marrow Dendritic Cells from Multiple Myeloma Patients
Science, June 20, 1997; 276(5320): 1851 - 1854.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS
http://www.peprotech.com/
Copyright © 1991 by AlphaMed Press.